Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
about
Emerging therapeutic biomarkers in endometrial cancerEpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosisNuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancerOverexpression of EpCAM and Trop2 in pituitary adenomasSubcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosisThe genomics and genetics of endometrial cancer.Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer.Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibodyPrimary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.Emerging therapeutic targets in endometrial cancer.Emerging drugs for endometrial cancer.EpCAM-Regulated Transcription Exerts Influences on Nanomechanical Properties of Endometrial Cancer Cells That Promote Epithelial-to-Mesenchymal Transition.Expression of CD133 in endometrial cancer cells and its implications.Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.Next-Generation Sequencing.
P2860
Q26865904-2D3134F4-239E-4386-8F3D-3A438B6815ABQ33616879-920509BC-0E9E-4836-B9C5-83BBFE9F6599Q33770286-C1A7542C-D87A-44AB-85F1-81903B46DFA3Q34308781-F7E57850-711D-4AA2-8EAD-CB9DA80C8771Q34437810-9FB0B012-690D-4D6A-8F42-5B1083C92657Q34634149-37452C32-4272-411D-8B3E-95D33A2051E1Q34733193-49104EE5-946A-443B-BD3C-6E526BC1D5F2Q36078946-641096CA-51E0-4220-B19B-4BD43B085CF1Q36151896-3E4DA853-D7A1-4161-8663-8D0770D43F1EQ36407948-1BDC88E8-BB31-4CB1-9E9D-C2D70B8603C4Q36949302-A23A80F3-258B-48A8-A250-1E4BA59943E7Q36983909-BA73B17C-7423-46AD-8F4F-535F741D84CBQ37827340-19B76ECB-F1C7-4680-BF8C-7A7B1080B86EQ38261469-B988C2CD-CE10-4F43-A27D-A733D1082B4DQ38734383-0066E98A-E614-4AE8-9F0A-D9CC24F21981Q41439970-A9B8CD70-F982-4713-B294-9D7A528C0DDDQ45849410-59C97FBC-E42F-43ED-8DA7-641BC60A35CBQ51032285-4A3486CA-7EA9-4228-8ABB-27BF57BC9891
P2860
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@ast
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@en
type
label
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@ast
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@en
prefLabel
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@ast
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@en
P2093
P2860
P1476
Overexpression of EpCAM in ute ...... antibody adecatumumab (MT201).
@en
P2093
Alessandro D Santin
Dan-Arin Silasi
Dominik Rüttinger
Emiliano Cocco
Fattaneh A Tavassoli
Karim El-Sahwi
Marta Bellone
Masoud Azodi
Maysa Abu-Khalaf
Natalia Buza
P2860
P356
10.1158/1535-7163.MCT-09-0675
P577
2010-01-06T00:00:00Z